Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Oncological Medicine
Volume 2018, Article ID 8672407, 5 pages
https://doi.org/10.1155/2018/8672407
Case Report

Adjuvant Radiochemotherapy with a 23-Month Overall Survival Time in a Patient after a Surgery due to Splenic Hemangiosarcoma Rupture: A Case Report with the Literature Review

1Chair and Department of Oncology, Medical University of Lublin, Lublin, Poland
2Radiation Therapy Department, Lublin Oncological Center, Lublin, Poland
3Chair and Department of Clinical Pathomorphology, Medical University of Lublin, Lublin, Poland
41st Gynecological Oncology and Gynecology Clinic, Independent Public Clinical Hospital No. 1 in Lublin, Lublin, Poland
5Brachytherapy Department, Lublin Oncological Center, Lublin, Poland
6Radiotherapy Department, Lublin Oncological Center, Lublin, Poland

Correspondence should be addressed to M. Bilski; moc.liamg@tamikslib

Received 31 July 2017; Revised 28 November 2017; Accepted 18 January 2018; Published 11 February 2018

Academic Editor: Peter F. Lenehan

Copyright © 2018 M. Bilski et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. M. Thompson, A. D. Levy, N. S. Aguilera, L. Gorospe, and R. M. Abbott, “Angiosarcoma of the spleen: imaging characteristics in 12 patients,” Radiology, vol. 235, no. 1, pp. 106–115, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Manouras, P. Giannopoulos, L. Toufektzian et al., “Splenic rupture as the presenting manifestation of primary splenic angiosarcoma in a teenage woman: a case report,” Journal of Medical Case Reports, vol. 2, no. 1, p. 133, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Falk, J. Krishnan, and J. M. Meis, “Primary angiosarcoma of the spleen, a clinicopathologic study of 40 cases,” The American Journal of Surgical Pathology, vol. 17, no. 10, pp. 959–970, 1993. View at Publisher · View at Google Scholar
  4. J. Sauer, “Primary and metastatic cancer of the spleen,” The Spleen, p. 192, 2011. View at Google Scholar
  5. S. Hu, C. E. Bueso-Ramos, S. Verstovsek et al., “Metastatic splenic angiosarcoma presenting with thrombocytopenia and bone marrow fibrosis mimicking idiopathic thrombocytopenic purpura and primary myelofibrosis: a diagnostic challenge,” Clinical Lymphoma Myeloma and Leukemia, vol. 13, no. 5, pp. 629–633, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. H. Jun-Te, C. Han-Ming, L. Chin-Yew et al., “Primary angiosarcoma of the spleen,” Journal of Surgical Oncology, vol. 92, no. 4, pp. 312–316, 2005. View at Google Scholar
  7. T. S. Neuhauser, G. A. Derringer, L. D. Thompson et al., “Splenic angiosarcoma: a clinicopathologic and immunophenotypic study of 28 cases,” Modern Pathology, vol. 13, no. 9, pp. 978–987, 2000. View at Publisher · View at Google Scholar
  8. N. Naka, M. Ohsawa, and Y. Tomita, “Prognostic factors in angiosarcoma: a multivariate analysis of 55 cases,” Journal of Surgical Oncology, vol. 61, no. 3, pp. 170–176, 1996. View at Publisher · View at Google Scholar
  9. F. Kohutek, L. Badik, and B. Bystricky, “Primary angiosarcoma of the spleen: rare diagnosis with atypical clinical course,” Case Reports in Oncological Medicine, vol. 2016, Article ID 4905726, 6 pages, 2016. View at Publisher · View at Google Scholar
  10. N. Penel, B. N. Bui, J. O. Bay et al., “Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study,” Journal of Clinical Oncology, vol. 26, no. 32, pp. 5269–5274, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. T. Hirata, K. Yonemori, M. Ando et al., “Efficacy of taxane regimens in patients with metastatic angiosarcoma,” European Journal of Dermatology, vol. 21, no. 4, pp. 539–545, 2011. View at Google Scholar
  12. W. Shon, S. M. Jenkins, D. T. Ross et al., “Angiosarcoma: a study of 98 cases with immunohistochemical evaluation of TLE3, a recently described marker of potential taxane responsiveness,” Journal of Cutaneous Pathology, vol. 38, no. 12, pp. 961–966, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Tobias, M. P. O’brien, and M. Agulnik, “Olaratumab for advanced soft tissue sarcoma,” Expert Review of Clinical Pharmacology, vol. 10, no. 7, pp. 699–705, 2017. View at Publisher · View at Google Scholar · View at Scopus
  14. C. Yoo, J. E. Kim, S. K. Yoon et al., “Angiosarcoma of the retroperitoneum: report on a patient treated with sunitinib,” Sarcoma, vol. 2009, Article ID 360875, 4 pages, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Alvarado-Miranda, L. Bacon-Fonseca, U. Lara-Medina et al., “Thalidomide combined with neoadjuvant chemotherapy in angiosarcoma of the breast with complete pathologic response: case report and review of literature,” Breast Care, vol. 8, no. 1, pp. 74–76, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. I. L. Ray-Coquard, J. Domont, E. Tresch-Bruneel et al., “Paclitaxel given once per week with or without bevacizumab in patients with advanced angiosarcoma: a randomized phase II trial,” Journal of Clinical Oncology, vol. 33, no. 25, pp. 2797–2802, 2015. View at Publisher · View at Google Scholar · View at Scopus
  17. L. K. Vitzthum, L. C. Brown, J. W. Rooney, and R. L. Foote, “Head and neck soft tissue sarcomas treated with radiation therapy,” Rare Tumors, vol. 8, no. 2, pp. 61–65, 2016. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Hata, H. Wada, I. Ogino et al., “Radiation therapy for angiosarcoma of the scalp: treatment outcomes of total scalp irradiation with X-rays and electrons,” Strahlentherapie und Onkologie, vol. 190, no. 10, pp. 899–904, 2014. View at Publisher · View at Google Scholar · View at Scopus